EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neonatal outcomes following magnesium sulfate exposure in the late preterm period (34 + 0–36 + 6 weeks)

Adi Shilony, Hila Shalev-Ram, Moran Weiss, Gal Cohen, Tal Biron-Shental, Gil Shechter-Maor

Archives of Gynecology and Obstetrics · 05.10.2026

DOI: 10.1007/s00404-026-08586-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 05.10.2026. Verfasst von Adi Shilony und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate whether antenatal magnesium sulfate exposure after 34 + 0 weeks’ gestation is associated with short and long-term neonatal outcomes in the late preterm period. Late-preterm birth was defined as delivery between 34 + 0 and 36 + 6 weeks of gestation.

Methods

This retrospective cohort study included children aged ≥ 2 years born at 34 + 0–36 + 6 weeks’ gestation to mothers with preeclampsia between 2013 and 2020. The primary exposure was antenatal magnesium sulfate administration. Short-term outcomes included respiratory distress, neonatal intensive care unit (NICU) admission, 5-min Apgar score ≤ 7, and umbilical cord pH ≤ 7.1. The effects of different exposure durations (< 6 h, 6–16 h, ≥ 17 h) and total dose (> 30 g) were also evaluated. The primary long-term outcome was parent-reported clinically diagnosed developmental delay (speech, cognitive, or motor), ascertained through a structured telephone questionnaire.

Results

Among 131 children born in the late preterm period, 59 (45%) were exposed to magnesium sulfate and 72 (55%) served as controls. Antenatal magnesium sulfate exposure was not associated with higher rates of respiratory distress, NICU admission, 5-min Apgar score ≤ 7, or cord pH ≤ 7.1. Findings were consistent across exposure durations and doses. Rates of developmental delay were similar between groups.

Conclusion

Magnesium sulfate administration after 34 + 0 weeks for maternal indications was not associated with statistically clear differences in the short-term neonatal or developmental outcomes assessed. However, the limited sample size, sparse adverse events, residual confounding, and incomplete long-term follow-up preclude conclusions regarding equivalence or safety.

Zitieren

APA

Shilony, A., Shalev-Ram, H., Weiss, M., Cohen, G., Biron-Shental, T., & Shechter-Maor, G. (2026). Neonatal outcomes following magnesium sulfate exposure in the late preterm period (34 + 0–36 + 6 weeks). Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-026-08586-x

Vancouver

Shilony A, Shalev-Ram H, Weiss M, Cohen G, Biron-Shental T, Shechter-Maor G. Neonatal outcomes following magnesium sulfate exposure in the late preterm period (34 + 0–36 + 6 weeks). Archives of Gynecology and Obstetrics. 2026. doi:10.1007/s00404-026-08586-x

BibTeX
@article{Shilony2026,
  author = {Shilony, Adi and Shalev-Ram, Hila and Weiss, Moran and Cohen, Gal and Biron-Shental, Tal and Shechter-Maor, Gil},
  title = {Neonatal outcomes following magnesium sulfate exposure in the late preterm period (34 + 0–36 + 6 weeks)},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2026},
  doi = {10.1007/s00404-026-08586-x}
}
Kostenlos starten →